Amgen Inc. (NASDAQ:AMGN) Shares Bought by Exeter Financial LLC

Exeter Financial LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% in the first quarter, HoldingsChannel.com reports. The fund owned 12,079 shares of the medical research company’s stock after purchasing an additional 85 shares during the period. Amgen makes up about 1.5% of Exeter Financial LLC’s investment portfolio, making the stock its 24th biggest position. Exeter Financial LLC’s holdings in Amgen were worth $3,238,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Amgen by 0.3% in the third quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after buying an additional 165,636 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Amgen by 3.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock valued at $1,890,769,000 after buying an additional 243,720 shares during the last quarter. Royal Bank of Canada raised its position in shares of Amgen by 14.8% in the fourth quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock valued at $1,679,625,000 after buying an additional 751,947 shares during the last quarter. Norges Bank acquired a new stake in shares of Amgen in the fourth quarter valued at about $1,556,912,000. Finally, California Public Employees Retirement System raised its position in shares of Amgen by 22.0% in the fourth quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company’s stock valued at $782,288,000 after buying an additional 490,539 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Up 0.0 %

Amgen stock traded up $0.07 during trading on Thursday, reaching $312.89. The stock had a trading volume of 877,626 shares, compared to its average volume of 2,775,602. Amgen Inc. has a 52-week low of $218.44 and a 52-week high of $329.72. The business has a 50 day moving average price of $299.67 and a 200 day moving average price of $291.67. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The stock has a market cap of $167.84 billion, a PE ratio of 45.00, a P/E/G ratio of 2.88 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. During the same quarter in the previous year, the firm earned $3.98 earnings per share. The firm’s quarterly revenue was up 22.0% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post 19.47 EPS for the current year.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.69% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AMGN. Barclays upgraded shares of Amgen from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $230.00 to $300.00 in a research report on Friday, May 3rd. TD Cowen cut their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Mizuho raised their price objective on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research report on Thursday, May 9th. Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. Finally, Truist Financial reaffirmed a “buy” rating and set a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $305.85.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.